Collection of Tissue Samples for Cancer Research



Status:Recruiting
Conditions:Cancer, Blood Cancer, Lymphoma, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any - 110
Updated:2/17/2019
Start Date:September 18, 2006
Contact:Nancy Moore, R.N.
Email:nancy.moore@nih.gov
Phone:(240) 760-6045

Use our guide to learn which trials are right for you!

Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)

Background:

-Patients who are being evaluated and/or treated at the NIH Clinical Center (pediatric and
adult) and adult patients at participating sites will be entered onto this tissue procurement
protocol for collection of tissue specimens.

Objectives:

- To obtain samples from adult and pediatric patients for research purposes from tests and
procedures that are done as required by the primary research protocol(s) to which a
patient is enrolled or as part of their standard-of-care treatment.

- To obtain samples for research purposes from non-surgical procedures, such as
percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or
biological fluids for this protocol.

Eligibility:

-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of
age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and
adult patients from participating sites.

Design:

- This is a multicenter tissue procurement protocol with NCI as the coordinating center.

- For adult patients: specimens for research purposes, as outlined in this protocol, will
be obtained from tests and procedures that are done as required by the primary research
protocols to which a patient is enrolled or as part of their standard-of-care treatment.
Non-surgical procedures, such as percutaneous biopsies, may also be performed for the
sole purpose of obtaining tissue specimens or biological fluids for this protocol.
Tissues and biological fluids to be procured may include but are not limited to blood,
serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial
alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These
specimens will be stored with unique identifiers and used to perform only those research
studies that are outlined in this protocol.

- For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical
model development will only be from tissue already being obtained as part of a procedure
necessary for the patient s clinical care or as part of a primary research protocol;
blood specimens will be collected as part of a blood collection already scheduled for
the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes
collected will not exceed institutional research limits.

- Given the risks associated with any invasive procedure, such as tumor biopsy, the
procedure will be discussed in detail with the patients and their parents/guardian (as
indicated), including the side effects, prior to obtaining a separate consent for each
procedure. A separate consent will not be signed prior to obtaining samples by minimally
invasive measures, such as venipuncture.

- This study has three separate consent forms: one for adult patients at the NIH Clinical
Center to opt to donate their samples for ongoing research on assay development and
studies of molecular pathways; and two for the generation of preclinical models (adult
and pediatric). Adult patients at the NIH and participating sites, and also pediatric
patients (NIH Clinical Center only), can opt to donate samples to create preclinical
models to study tumor biology and genetics, and to develop new therapies for cancer.

- Patients may remain on study for the duration of their consent or completion of the
planned procedure, whichever comes first.

Background:

-Patients who are being evaluated and/or treated at the NIH Clinical Center (pediatric and
adult) and adult patients at participating sites will be entered onto this tissue procurement
protocol for collection of tissue specimens.

Objectives:

- To obtain samples from adult and pediatric patients for research purposes from tests and
procedures that are done as required by the primary research protocol(s) to which a
patient is enrolled or as part of their standard-of-care treatment.

- To obtain samples for research purposes from non-surgical procedures, such as
percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or
biological fluids for this protocol.

Eligibility:

-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of
age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and
adult patients from participating sites.

Design:

- This is a multicenter tissue procurement protocol with NCI as the coordinating center.

- For adult patients: specimens for research purposes, as outlined in this protocol, will
be obtained from tests and procedures that are done as required by the primary research
protocols to which a patient is enrolled or as part of their standard-of-care treatment.
Non-surgical procedures, such as percutaneous biopsies, may also be performed on adult
patients at the NIH Clinical Center for the sole purpose of obtaining tissue specimens
or biological fluids for this protocol. Tissues and biological fluids to be procured may
include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural
fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair
follicles, and bone marrow. These specimens will be stored with unique identifiers and
used to perform only those research studies that are outlined in this protocol.

- For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical
model development will only be from tissue already being obtained as part of a procedure
necessary for the patient s clinical care or as part of a primary research protocol;
blood specimens will be collected as part of a blood collection already scheduled for
the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes
collected will not exceed institutional research limits.

- Given the risks associated with any invasive procedure, such as tumor biopsy, the
procedure will be discussed in detail with the patients and their parents/guardian (as
indicated), including the side effects, prior to obtaining a separate consent for each
procedure. A separate consent will not be signed prior to obtaining samples by minimally
invasive measures, such as venipuncture.

- This study has three separate consent forms: one for adult patients at the NIH Clinical
Center to opt to donate their samples for ongoing research on assay development and
studies of molecular pathways as listed in Section 8.2; and two for the generation of
preclinical models (adult and pediatric). Adult patients at the NIH and participating
sites, and also pediatric patients (NIH Clinical Center only), can opt to donate
specimens to create preclinical models to study tumor biology and genetics, and to
develop new therapies for cancer as described in Section 8.1.

- Patients may remain on study for the duration of their consent or completion of the
planned procedure, whichever comes first.

- INCLUSION CRITERIA - ADULT:

- Patients 18 years of age and older who are being evaluated and/or treated for cancer
at the NIH Clinical Center or at participating sites:

- Who have a newly diagnosed solid tumor, lymphoma or multiple myeloma malignancy
for which they have not yet received treatment, or

- Who have a previously treated solid tumor, lymphoma or multiple myeloma
malignancy that is now recurrent or currently progressing on treatment indicated
by:

- Radiographic evidence of tumor growth and/or new metastases, or

- documented evidence by the treating physician of signs/symptoms of clinical
disease progression, or

- Who are currently undergoing treatment (adjuvant, neoadjuvant, etc.), are within
the first two (2) cycles of treatment, and for whom disease response has not yet
been assessed

---In this circumstance, specimen collection should occur as distant in time from
the most recent drug administration as possible such as after completion of a
treatment cycle and immediately prior to initiation of the next cycle.

- For matched pair collections only (tissue + blood), patients with ongoing partial
response (PR) or stable disease (SD) are eligible.

- Confirmation of viable malignancy and/or <90% tumor necrosis must be
confirmed to the coordinating site, as indicated in the final pathology
report, for patients enrolled with PR or SD.

- ability to understand and willingness to sign a written informed consent document
indicating their willingness to have their tissue or biologic fluid specimens used for
research as outlined in this protocol.

EXCLUSION CRITERIA - ADULT:

- Patients with invasive fungal infections

- Patients with active and/or uncontrolled infections or who are still recovering from
an infection:

- Actively febrile patients with uncertain etiology of febrile episode

- All antibiotics should be completed at least 1 week (7 days) prior to collection

- No recurrence of fever or other symptoms related to infection for at least 1 week
(7 days) following completion of antibiotics

- Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion.

- Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e.,
quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of
HCV or HBV. Testing for hepatitis B or other infections for eligibility will be
performed only if clinically indicated.

- Patients with Hepatitis A as indicated by anti-HAV IgM reactivity

--Note: Patients that are anti-HAV IgG reactive only are not excluded

- Specimen collections from patients with benign tumors including but not limited to
desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response
(CR) based on imaging.

- Blood only collections from patients with partial or stable disease response:

- Blood will not be collected from patients whose disease demonstrates ongoing
partial response or ongoing (i.e., prolonged) stable disease given the poor rate
of model generation from such samples.

- Blood will not be collected from patients between doses within a single treatment
cycle.

INCLUSION CRITERIA - PEDIATRIC:

- Patients younger than 18 years of age with a histologically or cytologically confirmed
diagnosis of cancer (solid tumor, lymphoma or multiple myeloma) who are being treated
for cancer at the NIH Clinical Center and who will already be undergoing a clinically
necessary medical procedure during which tumor tissue will be resected or needle
biopsy tissue collected.

- Ability to understand and willingness to sign a written informed consent document
indicating their willingness to have their tissue or blood/biological fluid samples
used for research as outlined in this protocol, or, consent from a parent/guardian
with assent from the child.

EXCLUSION CRITERIA - PEDIATRIC:

- Patients with invasive fungal infections

- Patients with active and/or uncontrolled infections or who are still recovering from
an infection:

- Actively febrile patients with uncertain etiology of febrile episode

- All antibiotics should be completed at least 1 week (7 days) prior to collection

- No recurrence of fever or other symptoms related to infection for at least 1 week
(7 days) following completion of antibiotics

- Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion.

- Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e.,
quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of
HCV or HBV. Testing for hepatitis B or other infections for eligibility will be
performed only if clinically indicated.

- Patients with Hepatitis A as indicated by anti-HAV IgM reactivity

--Note: Patients that are anti-HAV IgG reactive only are not excluded

- Specimen collections from patients with benign tumors including but not limited to
desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response
(CR) based on imaging.

- Blood only collections from patients with partial or stable disease response:

- Blood will not be collected from patients whose disease demonstrates ongoing
partial response or ongoing (i.e., prolonged) stable disease given the poor rate
of model generation from such samples.

- Blood will not be collected from patients between doses within a single treatment
cycle.
We found this trial at
11
sites
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Phone: 206-543-6116
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Phone: 716-845-3284
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Phone: 319-467-5129
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Phone: 734-232-9408
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
9000 Rockville Pike
Bethesda, Maryland 20892
Phone: 888-624-1937
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Phone: 843-792-1512
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Phone: 434-982-4408
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Phone: 614-685-6778
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Phone: 317-944-0920
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Phone: 615-936-1512
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Phone: 314-286-1694
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials